Stingray Bio

Stingray Bio is a biotechnology company that develops small molecule inhibitors to target specific kinase pathways implicated in cancer. Founded in 2020 as a spin-out from the University of Sussex, the company is headquartered in Cambridge, UK. The company's creation is the result of over a decade of research by its founders, Professor Georgios Giamas and Professor John Spencer, at the University of Sussex.

Professor Giamas's laboratory identified that the protein "LMTK3" is persistent in several cancers, particularly breast cancer. Building on this discovery, Professors Giamas and Spencer created early drug-like molecules that suppress LMTK3, causing breast cancer cells to stop growing and die in laboratory studies. Stingray Bio was launched to translate this academic research into new therapies for breast cancer and potentially other cancers. The business model is focused on advancing these novel drug inhibitors of LMTK3 kinase signaling through the necessary testing to begin human trials, with the ultimate goal of providing new, effective treatments for cancer patients.

Upon its launch, Stingray Bio secured seed funding from the UK-based venture capital firm o2h Ventures, as well as grant funding from Innovate UK. This initial capital is being used to develop more advanced drugs targeting LMTK3. The company operates in the drug discovery industry, leveraging expertise in structural biology and cancer pharmacology to develop next-generation oncology therapeutics.

Keywords: LMTK3 inhibitors, small molecule inhibitors, kinase signaling pathway, cancer therapeutics, drug discovery, oncology, breast cancer, structural biology, cancer pharmacology, preclinical models, o2h Ventures, University of Sussex spin-out, cancer research, targeted therapy, new medicines, biotechnology, kinase targets